1. Biomarkers and Prediction of Prognosis in Transthyretin-Related Cardiac Amyloidosis: Direct Comparison of Two Staging Systems
- Author
-
Giulia Taborchi, Elisa Vignini, Massimo Di Gioia, Raffaele Martone, Sofia Morini, Carlo Di Mario, Federico Perfetto, Martina Gabriele, Simone Bartolini, Marco Allinovi, and Francesco Cappelli
- Subjects
Male ,Oncology ,medicine.medical_specialty ,Heart disease ,medicine.drug_class ,Renal function ,030204 cardiovascular system & hematology ,Severity of Illness Index ,03 medical and health sciences ,0302 clinical medicine ,Interquartile range ,Internal medicine ,Natriuretic Peptide, Brain ,Troponin I ,Natriuretic peptide ,medicine ,Humans ,030212 general & internal medicine ,Stage (cooking) ,Aged ,Retrospective Studies ,Aged, 80 and over ,Amyloid Neuropathies, Familial ,business.industry ,Prognosis ,medicine.disease ,Peptide Fragments ,Cardiac amyloidosis ,Biomarker (medicine) ,Female ,Cardiomyopathies ,Cardiology and Cardiovascular Medicine ,business ,Biomarkers ,Glomerular Filtration Rate - Abstract
The severity of heart disease varies widely among patients with transthyretin-related cardiac amyloidosis (ATTR-CA) at presentation, and availability of tools able to predict prognosis is essential for clinical and research purposes. Currently, two biomarker-based staging systems are available. The aim of this study was to compare their predictive performance.A total of 175 patients diagnosed with ATTR-CA (133 wild-type and 42 hereditary) were stratified into different stages based on 2 systems: the first system included N-terminal pro-B-type natriuretic peptide (NT-proBNP) and estimated glomerular filtration rate (eGFR), and the second one included NT-proBNP and troponin I (TnI). Survival estimates and age-adjusted survival for all-cause mortality were analysed over a median follow-up of 27 months (interquartile range 16-43 months).Predictive performance was more accurate when NT-proBNP and eGFR were used, resulting in effective survival stratification: 64.4 months for stage 1, 44.6 months for stage 2, and 20.5 months for stage 3 (P0.01 for stages 1 vs 2; P0.0001 for stages 1 vs 3; P0.0001 stages 2 vs 3). The combination of NT-proBNP and TnI was unable to effectively differentiate survival: 64.5 months for stage 1, 50.9 months for stage 2, and 27.3 months for stage 3 (P = 0.223 for stages 1 vs 2; P0.0001 for stages 1 vs 3; P0.0001 for stages 2 vs 3). The same results were seen after age adjustment.A staging system using NT-proBNP and eGFR had better prognostic accuracy for ATTR-CA patients compared with one using NTproBNP and TnI.
- Published
- 2020
- Full Text
- View/download PDF